StockTipsArenaBeta

BUY Granules India — Vikas Sethi, Sethi Finmart

BUYGranules India
Granules India share price target & all analyst calls

byVikas Sethi, Sethi FinmartHorizon: NA (inferred 1 year)12 Nov 2026via Zee Business (Live)

Entry₹815Inferred
Target₹950
Total upside +16.56%
Stop loss₹740-9.20% risk
CMP₹813.21d ago
Active-0.22%+16.82%upside left 12 mo left
Follow Vikas Sethi for new calls(38% target hit, 42 closed calls)Get alertsWatch GRANULES for new buy/sell callsGet alertsSee 8 other Long-term calls on GRANULESSee 272 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 15 Nov, 3:25 am IST
12 supporting7 neutral6 opposing
Supports the BUY call (12)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·13 Nov · yesterday

Zydus Lifesciences, Granules India offer growth opportunities over next 3-5 years: Shanika Capital

NewsCnbc-Tv18·9 Nov · 5d ago

(opens in new tab)

Shanika Capital's Anmol Ganjoo sees Zydus Lifesciences, Granules India among potential pharma winner

NewsCnbc-Tv18·9 Nov · 5d ago

(opens in new tab)

4 other SEBI-registered advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · same horizon·3 Nov · 2w ago

Granules India Q2 Results: Net profit jumps 39% on higher revenue, EBITDA margin improves

NewsCnbc-Tv18·2 Nov · 2w ago

(opens in new tab)
Neutral / worth noting (7)

Granules India Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·2 Nov · 2w ago

(opens in new tab)

Granules India's Gagillapur facility received 11 observations from the USFDA following an inspection. The company stated none relate to data integrity or cross-contamination and there is no impact on

BSE · Company Update·30 Oct · 2w ago

(opens in new tab)

Granules India Gagillapur FDA Inspection and Manufacturing Compliance Explained

NewsGoogle News·19 Oct · 4w ago

(opens in new tab)
Weighs against the BUY call (6)

Here's why Granules India shares could see a reaction on Monday

NewsCnbc-Tv18·31 Oct · 2w ago

(opens in new tab)

Granules India’s Gagillapur facility gets 11 observations in USFDA inspection

NewsCnbc-Tv18·30 Oct · 2w ago

(opens in new tab)

Granules India's Gagillapur manufacturing facility received eleven observations from the USFDA following an inspection.

NSE · Press Release·30 Oct · 2w ago

(opens in new tab)

Granules India Faces US FDA Inspection At Gagillapur Facility

NewsGoogle News·19 Oct · 4w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Granules India

All analyst calls on Granules India

More from Vikas Sethi, Sethi Finmart

Every call and its outcome